Kimia Biosciences Ltd Approves Changes in Director Tenure and Management Terms
Kimia Biosciences Ltd announced outcomes from its Board of Directors meeting held on April 18, 2026, detailing changes in the company’s directorship and management structure.The Board took note of the mandatory cessation of an Independent Director, approved the appointment of a new Additional Director, and modified the re-appointment terms for the Managing Director. Furthermore, the Board approved the reconstitution of several key Board Committees.
Cessation of Independent Director
The Board acknowledged the cessation of Ms. Richa Gupta, Independent Director. Her tenure concluded with effect from April 14, 2026, upon completing her maximum tenure of ten years. The company expressed its appreciation for Ms. Gupta's guidance during her service.| Particulars | Details |
|---|---|
| Name of Director | Ms. Richa Gupta (DIN- 07481646) |
| Date of Cessation | April 14, 2026 (Close of Business Hours) |
| Reason for Cessation | Completion of second term / maximum tenure of ten years |
Appointment of Additional Director
The Board approved the appointment of Mr. Amulya Kumar Nayak as an Additional Director, categorized as Non-Executive, Non-Independent. This appointment is effective from April 18, 2026, and is liable to retire by rotation, subject to the approval of shareholders at the ensuing General Meeting or Postal Ballot.Mr. Nayak is a seasoned finance and accounts professional with over 32 years of experience in areas including finance, accounts, taxation, audit, MIS, budgeting, banking, and commercial functions.
| Particulars | Details |
|---|---|
| Name | Mr. Amulya Kumar Nayak |
| Date of Appointment | April 18, 2026 |
| Role | Additional Director (Non-Executive, Non-Independent) |
| Term | From date of appointment till ensuing AGM, subject to shareholder approval |
| Relationship Disclosure | Not related to any Director of the Company |
Modification in Managing Director’s Terms
The Board also approved modifications to the terms of re-appointment for Mr. Sameer Goel, Managing Director. These modifications relate to his re-appointment for a further term effective from March 29, 2026.The Board approved that Mr. Sameer Goel shall be liable to retire by rotation. Apart from this modification, all other terms and conditions of his re-appointment remain unchanged.
Committee Reconstitution
Following the changes in directorship, the Board approved the immediate reconstitution of the company's committees. The Nomination & Remuneration Committee (NRC) was reconstituted with the following members:- Mr. Amulya Kumar Nayak - Non-Executive Director
- Mr. Avinash Prabhat - Independent Director
- Ms. Reema Goyal - Independent Woman Director
Stock Price Movement
Kimia Biosciences Ltd settled at ₹37.97 on Friday, edging higher after gaining 0.77% for the day. The shares tracked throughout the session, testing a range from ₹37.31 up to a high of ₹38.50.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.